Beyond lowering LDL cholesterol

被引:5
|
作者
Bayturan, Ozgur [1 ]
Utuk, Ozan [1 ]
Tuzcu, E. Murat [2 ]
机构
[1] Celal Bayar Univ, Tip Fak, Kardiyol Anabilim Dali, Manisa, Turkey
[2] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2011年 / 11卷 / 02期
关键词
Residual risk; LDL; atherogenic dyslipidemia; apolipoprotein B; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL; VERY-LOW LEVELS; PHOSPHOLIPASE A(2); CARDIOVASCULAR EVENTS; HDL CHOLESTEROL; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; APOLIPOPROTEIN-B;
D O I
10.5152/akd.2011.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Compelling evidence from randomized controlled studies demonstrated the crucial role of lowering low-density lipoprotein cholesterol (LDL-C) in the prevention of vascular events. However, not all patients with low LDL-C levels show similar reduction in event rates. The residual risk factors associated with ongoing vascular events despite achieving low LDL-C levels remain to be elucidated. New data suggest that beyond statin therapy, inflammatory mediators, high non-HDL (high-density lipoprotein) cholesterol or apolipoprotein B, small dense LDL-C, type 2 diabetes mellitus, and lifestyle features may have impact on residual vascular risk. In this review, we discussed the significance of identifying these residual risk factors and developing new treatment strategies to further decrease vascular events. The importance of imaging arterial wall to evaluate the effect of various medical therapies has also stated. (Anadolu Kardiyol Derg 2011; 11: 163-7)
引用
收藏
页码:163 / 167
页数:5
相关论文
共 50 条
  • [41] On the current debate on lowering LDL cholesterol with ezetimibe Reply
    Erdmann, Erland
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (44) : 2202 - 2202
  • [42] Emerging lipid lowering agents targeting LDL cholesterol
    Wojcik, Cezary
    POSTGRADUATE MEDICINE, 2020, 132 (05) : 433 - 440
  • [43] Efficacy and safety of more intensive lowering of LDL cholesterol
    Giral, Philippe
    Moulin, Philippe
    Rosenbaum, David
    LANCET, 2011, 377 (9767): : 715 - 715
  • [44] The final word about LDL-cholesterol lowering
    Streja, Dan
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2018, 25 (02) : 101 - 102
  • [45] Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol
    Lappegard, Knut Tore
    Enebakk, Terje
    Thunhaug, Hilde
    Hovland, Anders
    ATHEROSCLEROSIS, 2016, 251 : 119 - 123
  • [46] Analyzing IMPROVE-IT Beyond LDL Cholesterol
    Makhmudova, Umidakhon
    Luetjohann, Dieter
    Schulze, P. Christian
    Davis, Harry R.
    Weingaertner, Oliver
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (04) : E151 - E152
  • [47] Statin therapy in ARAS: Beyond cholesterol lowering
    Meier, Pascal
    AMERICAN JOURNAL OF HYPERTENSION, 2008, 21 (10) : 1075 - 1075
  • [48] Soy and cardiovascular disease: Cholesterol lowering and beyond
    Anthony, MS
    JOURNAL OF NUTRITION, 2000, 130 (03): : 662S - 663S
  • [49] Rosuvastatin: Beyond the cholesterol-lowering effect
    Cortese, Francesca
    Gesualdo, Michele
    Cortese, Annamaria
    Carbonara, Santa
    Devito, Fiorella
    Zito, Annapaola
    Ricci, Gabriella
    Scicchitano, Pietro
    Ciccone, Marco Matteo
    PHARMACOLOGICAL RESEARCH, 2016, 107 : 1 - 18
  • [50] Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol
    Wu, Peitao
    Moon, Jee-Young
    Daghlas, Iyas
    Franco, Giulianini
    Porneala, Bianca C.
    Ahmadizar, Fariba
    Richardson, Tom G.
    Isaksen, Jonas L.
    Hindy, Georgy
    Yao, Jie
    Sitlani, Colleen M.
    Raffield, Laura M.
    Yanek, Lisa R.
    Feitosa, Mary F.
    Cuadrat, Rafael R. C.
    Qi, Qibin
    Ikram, M. Arfan
    Ellervik, Christina
    Ericson, Ulrika
    Goodarzi, Mark O.
    Brody, Jennifer A.
    Lange, Leslie
    Mercader, Josep M.
    Vaidya, Dhananjay
    An, Ping
    Schulze, Matthias B.
    Masana, Lluis
    Ghanbari, Mohsen
    Olesen, Morten S.
    Cai, Jianwen
    Guo, Xiuqing
    Floyd, James S.
    Jaeger, Susanne
    Province, Michael A.
    Kalyani, Rita R.
    Psaty, Bruce M.
    Orho-Melander, Marju
    Ridker, Paul M.
    Kanters, Jorgen K.
    Uitterlinden, Andre
    Smith, George Davey
    Gill, Dipender
    Kaplan, Robert C.
    Kavousi, Maryam
    Raghavan, Sridharan
    Chasman, Daniel, I
    Rotter, Jerome, I
    Meigs, James B.
    Florez, Jose C.
    Dupuis, Josee
    DIABETES CARE, 2022, 45 (01) : 232 - 240